Researchers engineer 'protein switch' to dissect role of cancer's key players

April 10, 2013
At top is a structural model of uniRapR domain which binds small molecule rapamycin. The bottom left depicts inactive state of the protein of interest modified with uniRapR domain. Binding of rapamycin and uniRapR reactivates the protein (bottom right). Credit: Dokholyan Lab, UNC School of Medicine

Researchers at the University of North Carolina at Chapel Hill School of Medicine have "rationally rewired" some of the cell's smallest components to create proteins that can be switched on or off by command. These "protein switches" can be used to interrogate the inner workings of each cell, helping scientists uncover the molecular mechanisms of human health and disease.

In the first application of this approach, the UNC researchers showed how a protein called Src kinase influences the way extend and move, a previously unknown role that is consistent with the protein's ties to and metastasis.

"This rationally designed control of protein conformations represents a breakthrough in computational ," said senior study author Nikolay Dokholyan, PhD, a professor of biochemistry and biophysics. "We now have a new tool for delineating the activities of various proteins in living cells in a way that was never before possible."

The research was published online ahead of print in the Proceedings of the National Academy of Sciences. In the study, Dokholyan created a "switch" that would make a protein wobbly and unable to do its job unless it was flipped "on" by a drug called , which would stabilize the protein and let it perform its function.

The approach is a simpler and more reliable version of a system pioneered three years ago by Dokholyan and Klaus Hahn, professor of pharmacology at UNC, called rapamycin regulated or RapR. In the old approach, the switching mechanism depended on two proteins and the drug. The first protein – the one the researchers wanted to study – was given the RapR modification and put in cells in tissue culture. The second protein was placed in the cells as well, but simply floated around until the addition of drug caused it to latch on to the modification in the first protein and turn it on. The problem with the approach was that some cells would have a lot of the first protein and less of the second, or vice versa.

"It became the Achilles heel of the technique, because there was variability in the results due to the different ratios between the proteins," said Hahn. "What Dokholyan was able to do, which was extremely challenging from a protein engineering standpoint, was to combine the two parts into one."

Dokholyan and his colleagues took the two proteins and broke them apart into their individual components, structures called alpha helices and beta sheets. They then rewired them together to make a whole new protein where the parts could interact with each other. When researchers compared this system, called uniRapR, with the previous approach, they found the new one gave cleaner, more reliable and more consistent results.

They then applied the technique to study Src kinase, a protein involved in the metastasis or spread of tumor cells. Scientists had postulated that Src kinase plays a role in cell motility, but previous methods have not allowed them to isolate its activity from other similar proteins.

Working both in cultured human cells and in the model organism zebrafish, the researchers showed that turning on Src causes the cell to extend its edges as part of cell movement. Now that they have dissected the role of one , the researchers plan to look at a variety of other kinases to understand their roles in the development, progression, and spread of cancer.

Explore further: Discovery that specific protein modification important in cancer development

Related Stories

Discovery that specific protein modification important in cancer development

February 1, 2013
All proteins are made from chains of amino acids and their functions can be modified by adding small molecules to specific amino acids. One such modification is the addition of a methyl group, which is made of one carbon ...

Map of substrate-kinase interactions may lead to more effective cancer drugs

March 27, 2012
(Medical Xpress) -- Later-stage cancers thrive by finding detours around roadblocks that cancer drugs put in their path, but a Purdue University biochemist is creating maps that will help drugmakers close more routes and ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.